Hana Pharmaceutical Obtains Domestic Approval for General Anesthetic 'Remimazolam'
[Asia Economy Reporter Jang Hyowon] Hana Pharmaceutical announced on the 7th that it has obtained domestic approval from the Ministry of Food and Drug Safety for the general anesthetic 'Remimazolam.'
The target indication is the induction and maintenance of general anesthesia. The differences from competing products include ▲rapid anesthesia induction and postoperative recovery ▲reversibility with flumazenil if necessary, ensuring safety ▲excellent hemodynamic stability, among others.
Hana Pharmaceutical stated, "We plan to launch Remimazolam in South Korea within 2021 for the indication of general anesthesia," adding, "We hold exclusive sales rights for Remimazolam in six Southeast Asian countries (Vietnam, Indonesia, Thailand, the Philippines, Singapore, Malaysia) and are currently in discussions with pharmaceutical companies in each target country to enter the Southeast Asian market."
Hot Picks Today
"Samsung and Hynix Were Once for the Underachievers"... Hyundai Motor Employee's Lament
- "Was This Delicious Treat Enjoyed Only by Koreans?"... The K-Dessert Captivating Japan
- Han Donghoon Criticizes Hong Joonpyo: "Even If He Defects to the Democratic Party, They Won't Accept Him" for Defending Jeong Wono
- Despite Captivating the Nation for Over a Month... "Timmy" the Whale Ultimately Found Dead
- "That? It's Already Stashed" Nightlife Scene Crosses the Line [ChwiYak Nation] ③
Furthermore, they added, "We plan to additionally obtain indications for Remimazolam for procedural sedation and ICU sedation beyond the general anesthesia indication in the future."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
